Butalamine

This classification denotes a vasodilating agent with the molecular formula C18H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140T9JTG43, chemically known as 1,2-ethanediamine, n,n-dibutyl-n-(3-phenyl-1,2,4-oxadiazol-5-yl)- but generally known as butalamine, which bears US NIH Compound Identifier 30949. Butalamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05998MIG. The term BUTALAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules butalamine in its Anatomical Therapeutic Chemical (ATC) Classification. BUTALAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butalamine under HS 29349990 and SITC 51579. As of Q4 2014, BUTALAMINE remains the US FDA Preferred Term for this commodity. Butalamine bears US NLM identifiers UMLS ID C0644503 and NCI Concept Code C77071. SMILES: o1nc(nc1NCCN(CCCC)CCCC)c1ccccc1.